<DOC>
	<DOCNO>NCT00823186</DOCNO>
	<brief_summary>This phase I study design establish optimal dose paclitaxel , fix cisplatin dose 40 mg/m2 , deliver every week three week , neoadjuvant therapy radical hysterectomy bulky ( FIGO IB2 FIGO IIA primary tumor dimension &gt; 4 cm ) squamous cell cervical cancer . This study conduct branch Chang Gung Memorial Hospital . The start dose paclitaxel 50 mg/m2 , escalate increment 10 mg/m2 maximum dose 80 mg/m2 . The drug administer sequentially ( paclitaxel first , follow cisplatin ) within one day every week three cycle . A cohort 3 patient , assessable toxicity , treat dose level . Each patient receive fix dose paclitaxel cisplatin , without modification . If none first 3 patient experience dose limit toxicity ( DLT , see definition paragraph ) , escalation next dose level proceed . If one patient develop DLT , cohort expand 6 patient . If 1 6 patient experience DLT , escalation next dose level proceed . The maximum tolerated dose ( MTD ) high dose level 1 6 patient experience DLT . This dose level consider recommend dose Phase II study . Although efficacy evaluation main purpose study , response rate 60 % , evaluate immediately surgery , case undergo 2 cycle therapy preset requirement phase II study use regimen.The primary goal NAC cervical cancer improve feasibility surgical treatment , radical hysterectomy , without delay schedule surgery increase surgical risk morbidity . Therefore , definition DLT NAC respond principle , addition standard dose-limiting toxicity phase I study .</brief_summary>
	<brief_title>Dose-finding Study Weekly Paclitaxel Cisplatin FIGO IB2 Bulky IIA Cervical Cancer</brief_title>
	<detailed_description>This multi-center , open-label , phase I study paclitaxel cisplatin neoadjuvant therapy patient FIGO IB2 bulky IIA , squamous cell cervical carcinoma uterine cervix . The study mainly dose-finding paclitaxel , combine fix cisplatinum dose , neoadjuvant chemotherapy weekly basis . The optimal dose paclitaxel principally define high dose allow least 5/6 patient , NAC , undergo schedule radical hysterectomy . A subsequent toxicity assessment evaluate impact neoadjuvant chemotherapy recovery follow radical hysterectomy , efficacy assessment set second purpose study . Primary Objectives : - establish optimal dose weekly cisplatin plus paclitaxel 3 cycle neoadjuvant chemotherapy ( NAC ) FIGO IB2 bulky IIA , squamous cell cervical cancer , follow radical hysterectomy pelvic lymphadenectomy Secondary Objectives : - evaluate toxicity study regimen impact radical hysterectomy neoadjuvant chemotherapy - evaluate overall tumor response neoadjuvant chemotherapy An estimate 8 21 patient enrol study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>woman age 3570 year follow criterion : untreated , histologically confirm squamous cell carcinoma uterine cervix FIGO stage IB2 bulky IIA , tumor extension limit within upper one third vaginal wall . Bulky tumor define ( ) visible cervical tumor large diameter &gt; 4 cm ( b ) cervix expand &gt; 4 cm result tumor infiltration pelvic examination verify magnetic resonance image ( MRI ) , 3dimensional ( D ) compute tomography ( CT ) , 3D ultrasound study suspicious lymph node metastasis enlarge lymph node extrapelvic spread cancer detect MRI , negative cytologic histologic study suspicious node ( ) ( also participate PETCT monitoring response trial , abnormal FDG uptake pelvic node ( ) without prove nodal extrapelvic metastasis eligible ) Histological cytological document pelvic lymph node extrapelvic metastasis , concurrent history malignant tumor ( ) treat nonmelanoma skin cancer undergone surgical procedure cervical biopsy receive cytotoxic procedure include chemotherapy , radiotherapy treatment biologic response modifier ( ) cervical tumor participate investigational treatment cervical cancer history allergic reaction platinum paclitaxel uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement pregnant breast feed woman , urinary pregnancy test must perform patient childbearing potential entering study result must negative</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>cervical carcinoma</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
</DOC>